Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd VYYRF


Primary Symbol: V.VM

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by lscfaon Oct 09, 2024 10:52am
146 Views
Post# 36259334

New info?

New info?

https://stockhouse.com/news/newswire/2024/10/03/one-best-venture-pharma-stocks-has-grown-even-stronger

 




Additional products in development

Voyageur has four additional products at late stages of development:

  • Vision HD 98 per cent: High-density (98 per cent weight-per-weight (w/w)) barium sulfate powder for upper GI double-contrast radiographic examinations.
  • Vision LD 96 per cent: Versatile high-density (57 per cent w/w to 156 per cent w/w) barium sulfate powder for single contrast radiographic examinations of the upper and lower GI tract.
  • Smooth HD 105 per cent: High-density (105 per cent weight-by-volume (w/v), 58 per cent w/w) barium sulfate suspension for upper GI esophagogram and double contrast studies.
  • Smooth LD 60 per cent: Low-density (60 per cent w/v) barium sulfate suspension solution for single contrast radiographic examinations of the esophagus, stomach, and small bowel.
<< Previous
Bullboard Posts
Next >>